Human Gene PDGFRB (ENST00000261799.9_7) from GENCODE V47lift37
  Description: platelet derived growth factor receptor beta, transcript variant 1 (from RefSeq NM_002609.4)
Gencode Transcript: ENST00000261799.9_7
Gencode Gene: ENSG00000113721.14_9
Transcript (Including UTRs)
   Position: hg19 chr5:149,493,402-149,535,408 Size: 42,007 Total Exon Count: 23 Strand: -
Coding Region
   Position: hg19 chr5:149,495,326-149,516,610 Size: 21,285 Coding Exon Count: 22 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesGeneReviewsModel Information
Methods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr5:149,493,402-149,535,408)mRNA (may differ from genome)Protein (1106 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: PGFRB_HUMAN
DESCRIPTION: RecName: Full=Platelet-derived growth factor receptor beta; Short=PDGF-R-beta; Short=PDGFR-beta; EC=2.7.10.1; AltName: Full=Beta platelet-derived growth factor receptor; AltName: Full=Beta-type platelet-derived growth factor receptor; AltName: Full=CD140 antigen-like family member B; AltName: Full=Platelet-derived growth factor receptor 1; Short=PDGFR-1; AltName: CD_antigen=CD140b; Flags: Precursor;
FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5- trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.
CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
ENZYME REGULATION: Present in an inactive conformation in the absence of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by imatinib.
SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with heterodimers formed by PDGFA and PDGFB. May also interact with homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA homodimers and heterodimers with PDGFRB are observed. Interacts with SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. Interacts (tyrosine phosphorylated) with PIK3R1. Interacts (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by SHC1. Interacts (via C-terminus) with SLC9A3R1.
INTERACTION: Q05209:PTPN12; NbExp=2; IntAct=EBI-641237, EBI-2266035;
SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand binding, the autophosphorylated receptor is ubiquitinated and internalized, leading to its degradation.
PTM: Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is important for interaction with SRC family kinases. Phosphorylation at Tyr-740 and Tyr-751 is important for interaction with PIK3R1. Phosphorylation at Tyr-751 is important for interaction with NCK1. Phosphorylation at Tyr-771 and Tyr-857 is important for interaction with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient phosphorylation of PLCG1 and PTPN11, resulting in increased phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 is important for interaction with PTPN11. Phosphorylation at Tyr-1009 and Tyr-1021 is important for interaction with PLCG1. Phosphorylation at Tyr- 1021 is important for interaction with CBL; PLCG1 and CBL compete for the same binding site. Dephosphorylated by PTPRJ at Tyr-751, Tyr-857, Tyr-1009 and Tyr-1021.
PTM: N-glycosylated.
PTM: Ubiquitinated. After autophosphorylation, the receptor is polyubiquitinated, leading to its degradation.
DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).
DISEASE: Note=A chromosomal aberration involving PDGFRB may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with TRIP11. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia.
DISEASE: Note=A chromosomal aberration involving PDGFRB may be a cause of juvenile myelomonocytic leukemia. Translocation t(5;17)(q33;p11.2) with SPECC1.
DISEASE: Defects in PDGFRB are a cause of myeloproliferative disorder chronic with eosinophilia (MPE) [MIM:131440]. A hematologic disorder characterized by malignant eosinophils proliferation. Note=A chromosomal aberration involving PDGFRB is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein. Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 fusion protein.
DISEASE: Note=A chromosomal aberration involving PDGFRB may be the cause of a myeloproliferative disorder (MBD) associated with eosinophilia. Translocation t(1;5)(q23;q33) that forms a PDE4DIP- PDGFRB fusion protein.
DISEASE: Note=A chromosomal aberration involving PGFRB is found in a patient with T-lymphoblastic lymphoma (T-ALL) and an associated myeloproliferative neoplasm (MPN) with eosinophilia. Translocation t(5;6)(q33-34;q23) with CEP85L. The translocation fuses the 5'-end of CEP85L (isoform 4) to the 3'-end of PDGFRB.
SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like) domains.
SIMILARITY: Contains 1 protein kinase domain.
WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/PDGFRBID21ch5q32.html";

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: PDGFRB
Diseases sorted by gene-association score: kosaki overgrowth syndrome* (1579), myofibromatosis, infantile, 1* (1329), basal ganglia calcification, idiopathic, 4* (1230), premature aging syndrome, penttinen type* (1180), myeloproliferative disorder with eosinophilia* (979), infantile myofibromatosis* (775), myeloid/lymphoid neoplasm associated with pdgfrb rearrangement* (350), primary hypereosinophilic syndrome* (350), chronic myelomonocytic leukemia* (274), primary familial brain calcification* (260), primary familial brain calcification 4* (100), basal ganglia calcification (27), myeloproliferative neoplasm (24), dermatofibrosarcoma protuberans (19), hypereosinophilic syndrome (17), myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 (16), myeloid neoplasms associated with pdgfrb rearrangement (16), cellular neurofibroma (15), gastrointestinal stromal tumor (14), systemic mastocytosis (14), glioblastoma multiforme (12), desmoid tumor (11), hypereosinophilic syndrome, idiopathic, resistant to imatinib (9), mast cell disease (8), myelodysplastic syndrome (8), chronic eosinophilic leukemia (8), leukemia, chronic myeloid, somatic (8), atypical chronic myeloid leukemia (8), vascular cancer (8), myofascial pain syndrome (8), connective tissue benign neoplasm (7), leiomyosarcoma (7), bone marrow cancer (7), fibrosarcoma of bone (6), myofibroma (6), 8p11 myeloproliferative syndrome (6), tendinosis (6), moyamoya disease (6), polycythemia vera, somatic (6), adenocarcinoma (5), spinal chordoma (5), diabetic angiopathy (5), uterine sarcoma (5), hypotropia (5), glioblastoma (4), corneal dystrophy, subepithelial mucinous (4), malignant glioma (4), ewing sarcoma (3), astrocytoma (3), renal cell carcinoma (3), juvenile myelomonocytic leukemia (3), pancreatic cancer (2), lung cancer (2), breast cancer (2), prostate cancer (2), hematologic cancer (2), endometrial stromal sarcoma (2), leukocyte disease (1), ovarian cancer, somatic (1), meningioma, familial (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 128.79 RPKM in Cervix - Endocervix
Total median expression: 2063.16 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -186.50455-0.410 Picture PostScript Text
3' UTR -737.001924-0.383 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR007110 - Ig-like
IPR013783 - Ig-like_fold
IPR013098 - Ig_I-set
IPR003599 - Ig_sub
IPR003598 - Ig_sub2
IPR013151 - Immunoglobulin
IPR011009 - Kinase-like_dom
IPR000719 - Prot_kinase_cat_dom
IPR017441 - Protein_kinase_ATP_BS
IPR001245 - Ser-Thr/Tyr_kinase_cat_dom
IPR008266 - Tyr_kinase_AS
IPR020635 - Tyr_kinase_cat_dom
IPR016243 - Tyr_kinase_CSF1/PDGF_rcpt
IPR001824 - Tyr_kinase_rcpt_3_CS
IPR009134 - Tyr_kinase_VEGFR_rcpt_N

Pfam Domains:
PF00047 - Immunoglobulin domain
PF00069 - Protein kinase domain
PF07679 - Immunoglobulin I-set domain
PF07714 - Protein tyrosine and serine/threonine kinase
PF13895 - Immunoglobulin domain
PF13927 - Immunoglobulin domain

SCOP Domains:
48726 - Immunoglobulin
56112 - Protein kinase-like (PK-like)

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1GQ5 - X-ray MuPIT 1H9O - X-ray MuPIT 1LWP - Model 2L6W - NMR MuPIT 3MJG - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P09619
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGDEnsembl   
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000166 nucleotide binding
GO:0004672 protein kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0004992 platelet activating factor receptor activity
GO:0005017 platelet-derived growth factor-activated receptor activity
GO:0005019 platelet-derived growth factor beta-receptor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005102 receptor binding
GO:0005161 platelet-derived growth factor receptor binding
GO:0005515 protein binding
GO:0005524 ATP binding
GO:0016301 kinase activity
GO:0016740 transferase activity
GO:0019899 enzyme binding
GO:0019901 protein kinase binding
GO:0038085 vascular endothelial growth factor binding
GO:0043548 phosphatidylinositol 3-kinase binding
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0048407 platelet-derived growth factor binding

Biological Process:
GO:0000165 MAPK cascade
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006468 protein phosphorylation
GO:0006935 chemotaxis
GO:0007165 signal transduction
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway
GO:0007186 G-protein coupled receptor signaling pathway
GO:0007275 multicellular organism development
GO:0007568 aging
GO:0008284 positive regulation of cell proliferation
GO:0008584 male gonad development
GO:0009636 response to toxic substance
GO:0010863 positive regulation of phospholipase C activity
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014070 response to organic cyclic compound
GO:0014911 positive regulation of smooth muscle cell migration
GO:0016310 phosphorylation
GO:0016477 cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0030335 positive regulation of cell migration
GO:0032355 response to estradiol
GO:0032516 positive regulation of phosphoprotein phosphatase activity
GO:0032526 response to retinoic acid
GO:0032956 regulation of actin cytoskeleton organization
GO:0032967 positive regulation of collagen biosynthetic process
GO:0033993 response to lipid
GO:0034405 response to fluid shear stress
GO:0035025 positive regulation of Rho protein signal transduction
GO:0035441 cell migration involved in vasculogenesis
GO:0035556 intracellular signal transduction
GO:0035789 metanephric mesenchymal cell migration
GO:0035791 platelet-derived growth factor receptor-beta signaling pathway
GO:0035793 positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway
GO:0035909 aorta morphogenesis
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0038091 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway
GO:0042060 wound healing
GO:0042542 response to hydrogen peroxide
GO:0043065 positive regulation of apoptotic process
GO:0043066 negative regulation of apoptotic process
GO:0043406 positive regulation of MAP kinase activity
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0043627 response to estrogen
GO:0045840 positive regulation of mitotic nuclear division
GO:0046488 phosphatidylinositol metabolic process
GO:0046777 protein autophosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048146 positive regulation of fibroblast proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048839 inner ear development
GO:0050921 positive regulation of chemotaxis
GO:0051897 positive regulation of protein kinase B signaling
GO:0055003 cardiac myofibril assembly
GO:0055093 response to hyperoxia
GO:0060326 cell chemotaxis
GO:0060437 lung growth
GO:0060981 cell migration involved in coronary angiogenesis
GO:0061298 retina vasculature development in camera-type eye
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071670 smooth muscle cell chemotaxis
GO:0072075 metanephric mesenchyme development
GO:0072262 metanephric glomerular mesangial cell proliferation involved in metanephros development
GO:0072275 metanephric glomerulus morphogenesis
GO:0072277 metanephric glomerular capillary formation
GO:0072278 metanephric comma-shaped body morphogenesis
GO:0072284 metanephric S-shaped body morphogenesis
GO:0090280 positive regulation of calcium ion import
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000491 positive regulation of hepatic stellate cell activation
GO:2000573 positive regulation of DNA biosynthetic process

Cellular Component:
GO:0005634 nucleus
GO:0005737 cytoplasm
GO:0005764 lysosome
GO:0005794 Golgi apparatus
GO:0005886 plasma membrane
GO:0005925 focal adhesion
GO:0009986 cell surface
GO:0016020 membrane
GO:0016021 integral component of membrane
GO:0016324 apical plasma membrane
GO:0031226 intrinsic component of plasma membrane
GO:0031410 cytoplasmic vesicle
GO:0043202 lysosomal lumen
GO:0043231 intracellular membrane-bounded organelle


-  Descriptions from all associated GenBank mRNAs
  LF211063 - JP 2014500723-A/18566: Polycomb-Associated Non-Coding RNAs.
LP830501 - Sequence 3 from Patent EP3211090.
M21616 - Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds.
BC032224 - Homo sapiens platelet-derived growth factor receptor, beta polypeptide, mRNA (cDNA clone MGC:34052 IMAGE:5309813), complete cds.
J03278 - Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds.
JD504955 - Sequence 485979 from Patent EP1572962.
DM110845 - Novel Cancer Marker and Use Thereof.
LF343697 - JP 2014500723-A/151200: Polycomb-Associated Non-Coding RNAs.
JD053446 - Sequence 34470 from Patent EP1572962.
JD560401 - Sequence 541425 from Patent EP1572962.
JD408772 - Sequence 389796 from Patent EP1572962.
JD200222 - Sequence 181246 from Patent EP1572962.
LF343696 - JP 2014500723-A/151199: Polycomb-Associated Non-Coding RNAs.
JD187640 - Sequence 168664 from Patent EP1572962.
JD335737 - Sequence 316761 from Patent EP1572962.
JD263882 - Sequence 244906 from Patent EP1572962.
LF343695 - JP 2014500723-A/151198: Polycomb-Associated Non-Coding RNAs.
JD097333 - Sequence 78357 from Patent EP1572962.
JD358267 - Sequence 339291 from Patent EP1572962.
JD260464 - Sequence 241488 from Patent EP1572962.
JD284485 - Sequence 265509 from Patent EP1572962.
JD519310 - Sequence 500334 from Patent EP1572962.
JD384924 - Sequence 365948 from Patent EP1572962.
JD230205 - Sequence 211229 from Patent EP1572962.
JD362715 - Sequence 343739 from Patent EP1572962.
LF343694 - JP 2014500723-A/151197: Polycomb-Associated Non-Coding RNAs.
JD403097 - Sequence 384121 from Patent EP1572962.
LF343693 - JP 2014500723-A/151196: Polycomb-Associated Non-Coding RNAs.
JD195478 - Sequence 176502 from Patent EP1572962.
JD216964 - Sequence 197988 from Patent EP1572962.
JD321006 - Sequence 302030 from Patent EP1572962.
JD552946 - Sequence 533970 from Patent EP1572962.
AK293093 - Homo sapiens cDNA FLJ76012 complete cds, highly similar to Homo sapiens platelet-derived growth factor receptor, betapolypeptide (PDGFRB), mRNA.
JD552154 - Sequence 533178 from Patent EP1572962.
JD435340 - Sequence 416364 from Patent EP1572962.
JD384014 - Sequence 365038 from Patent EP1572962.
JD420608 - Sequence 401632 from Patent EP1572962.
JD442691 - Sequence 423715 from Patent EP1572962.
JD476394 - Sequence 457418 from Patent EP1572962.
JD306562 - Sequence 287586 from Patent EP1572962.
JD393452 - Sequence 374476 from Patent EP1572962.
JD120396 - Sequence 101420 from Patent EP1572962.
JD492519 - Sequence 473543 from Patent EP1572962.
JD157555 - Sequence 138579 from Patent EP1572962.
JD276240 - Sequence 257264 from Patent EP1572962.
AB209657 - Homo sapiens mRNA for platelet-derived growth factor receptor beta precursor variant protein.
LF343692 - JP 2014500723-A/151195: Polycomb-Associated Non-Coding RNAs.
DQ892124 - Synthetic construct clone IMAGE:100004754; FLH183240.01X; RZPDo839H11140D platelet-derived growth factor receptor, beta polypeptide (PDGFRB) gene, encodes complete protein.
JN003579 - Homo sapiens EBF1-PDGFRB fusion protein mRNA, complete cds.
LT626076 - Homo sapiens mRNA for Activated tyrosine kinase PDGFRB (NDEL1-PDGFRB gene).
KJ897314 - Synthetic construct Homo sapiens clone ccsbBroadEn_06708 PDGFRB gene, encodes complete protein.
EU176549 - Synthetic construct Homo sapiens clone IMAGE:100011461; FLH183239.01L; RZPDo839E09253D platelet-derived growth factor receptor, beta polypeptide (PDGFRB) gene, encodes complete protein.
AB385183 - Synthetic construct DNA, clone: pF1KB7023, Homo sapiens PDGFRB gene for beta platelet-derived growth factor receptor precursor, complete cds, without stop codon, in Flexi system.
LF343691 - JP 2014500723-A/151194: Polycomb-Associated Non-Coding RNAs.
LF343690 - JP 2014500723-A/151193: Polycomb-Associated Non-Coding RNAs.
LF343689 - JP 2014500723-A/151192: Polycomb-Associated Non-Coding RNAs.
LF343687 - JP 2014500723-A/151190: Polycomb-Associated Non-Coding RNAs.
LF343686 - JP 2014500723-A/151189: Polycomb-Associated Non-Coding RNAs.
LF343685 - JP 2014500723-A/151188: Polycomb-Associated Non-Coding RNAs.
LF343683 - JP 2014500723-A/151186: Polycomb-Associated Non-Coding RNAs.
LF343680 - JP 2014500723-A/151183: Polycomb-Associated Non-Coding RNAs.
EU826595 - Homo sapiens soluble PDGFRb variant 1 (PDGFRB) mRNA, complete cds, alternatively spliced.
LF343677 - JP 2014500723-A/151180: Polycomb-Associated Non-Coding RNAs.
LF343676 - JP 2014500723-A/151179: Polycomb-Associated Non-Coding RNAs.
CU689304 - Synthetic construct Homo sapiens gateway clone IMAGE:100020558 5' read PDGFRB mRNA.
LF343675 - JP 2014500723-A/151178: Polycomb-Associated Non-Coding RNAs.
LF343674 - JP 2014500723-A/151177: Polycomb-Associated Non-Coding RNAs.
LF343673 - JP 2014500723-A/151176: Polycomb-Associated Non-Coding RNAs.
LF343672 - JP 2014500723-A/151175: Polycomb-Associated Non-Coding RNAs.
M30493 - Human platelet-derived growth factor beta mRNA fragment.
LF343670 - JP 2014500723-A/151173: Polycomb-Associated Non-Coding RNAs.
LF343663 - JP 2014500723-A/151166: Polycomb-Associated Non-Coding RNAs.
JD236569 - Sequence 217593 from Patent EP1572962.
LF343662 - JP 2014500723-A/151165: Polycomb-Associated Non-Coding RNAs.
JD215026 - Sequence 196050 from Patent EP1572962.
JD285799 - Sequence 266823 from Patent EP1572962.
JD072717 - Sequence 53741 from Patent EP1572962.
JD372097 - Sequence 353121 from Patent EP1572962.
JD514642 - Sequence 495666 from Patent EP1572962.
JD072716 - Sequence 53740 from Patent EP1572962.
JD385045 - Sequence 366069 from Patent EP1572962.
JD134601 - Sequence 115625 from Patent EP1572962.
JD514852 - Sequence 495876 from Patent EP1572962.
JD126368 - Sequence 107392 from Patent EP1572962.
JD187150 - Sequence 168174 from Patent EP1572962.
JD278284 - Sequence 259308 from Patent EP1572962.
JD138614 - Sequence 119638 from Patent EP1572962.
JD231113 - Sequence 212137 from Patent EP1572962.
JD210427 - Sequence 191451 from Patent EP1572962.
MA579274 - JP 2018138019-A/151200: Polycomb-Associated Non-Coding RNAs.
MA579273 - JP 2018138019-A/151199: Polycomb-Associated Non-Coding RNAs.
MA579272 - JP 2018138019-A/151198: Polycomb-Associated Non-Coding RNAs.
MA579271 - JP 2018138019-A/151197: Polycomb-Associated Non-Coding RNAs.
MA579270 - JP 2018138019-A/151196: Polycomb-Associated Non-Coding RNAs.
MA579269 - JP 2018138019-A/151195: Polycomb-Associated Non-Coding RNAs.
MA579268 - JP 2018138019-A/151194: Polycomb-Associated Non-Coding RNAs.
MA579267 - JP 2018138019-A/151193: Polycomb-Associated Non-Coding RNAs.
MA579266 - JP 2018138019-A/151192: Polycomb-Associated Non-Coding RNAs.
MA579264 - JP 2018138019-A/151190: Polycomb-Associated Non-Coding RNAs.
MA579263 - JP 2018138019-A/151189: Polycomb-Associated Non-Coding RNAs.
MA579262 - JP 2018138019-A/151188: Polycomb-Associated Non-Coding RNAs.
MA579260 - JP 2018138019-A/151186: Polycomb-Associated Non-Coding RNAs.
MA579257 - JP 2018138019-A/151183: Polycomb-Associated Non-Coding RNAs.
MA579254 - JP 2018138019-A/151180: Polycomb-Associated Non-Coding RNAs.
MA579253 - JP 2018138019-A/151179: Polycomb-Associated Non-Coding RNAs.
MA579252 - JP 2018138019-A/151178: Polycomb-Associated Non-Coding RNAs.
MA579251 - JP 2018138019-A/151177: Polycomb-Associated Non-Coding RNAs.
MA579250 - JP 2018138019-A/151176: Polycomb-Associated Non-Coding RNAs.
MA579249 - JP 2018138019-A/151175: Polycomb-Associated Non-Coding RNAs.
MA579247 - JP 2018138019-A/151173: Polycomb-Associated Non-Coding RNAs.
MA579240 - JP 2018138019-A/151166: Polycomb-Associated Non-Coding RNAs.
MA579239 - JP 2018138019-A/151165: Polycomb-Associated Non-Coding RNAs.
MA446640 - JP 2018138019-A/18566: Polycomb-Associated Non-Coding RNAs.

-  Biochemical and Signaling Pathways
  Reactome (by CSHL, EBI, and GO)

Protein P09619 (Reactome details) participates in the following event(s):

R-HSA-389086 Autophosphorylation of PDGF alpha/beta receptors
R-HSA-186786 Autophosphorylation of PDGF beta receptors
R-HSA-186798 GAP binds to PDGF-beta receptors only
R-HSA-8864036 PTPN12 dephosphorylates PDGFRB at Y1021
R-HSA-186765 PLC-gamma binds to the active receptor
R-HSA-186778 SHP2 binds to the active receptor
R-HSA-186780 PI3-kinase binds to the active receptor
R-HSA-186819 SH2 domain of Src binds to the active receptor
R-HSA-186826 Grb2/Sos1 complex binds to the active receptor
R-HSA-380782 STAT binds to the active receptor
R-HSA-382055 Grb7 binds to the active PDGF receptor
R-HSA-382056 Crk binds to the active PDGF receptor
R-HSA-382058 Nck binds to the active PDGF receptor
R-HSA-1524182 Activated PLC gamma dissociates from the PDGF receptor
R-HSA-380780 Activation of Src
R-HSA-1524186 Phosphorylation of PLCgamma by PDGFR
R-HSA-382052 p130Cas and C3G bind PDGFR bound Crk
R-HSA-186800 PI3K catalyses the phosphorylation of PIP2 to PIP3
R-HSA-186834 Sos-mediated nucleotide exchange of Ras (PDGF receptor:Grb2:Sos)
R-HSA-2400009 PI3K inhibitors block PI3K catalytic activity
R-HSA-2316434 PI3K phosphorylates PIP2 to PIP3
R-HSA-5672965 RAS GEFs promote RAS nucleotide exchange
R-HSA-186797 Signaling by PDGF
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases
R-HSA-186763 Downstream signal transduction
R-HSA-162582 Signal Transduction
R-HSA-2219530 Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1257604 PIP3 activates AKT signaling
R-HSA-6811558 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-5673001 RAF/MAP kinase cascade
R-HSA-2219528 PI3K/AKT Signaling in Cancer
R-HSA-9006925 Intracellular signaling by second messengers
R-HSA-199418 Negative regulation of the PI3K/AKT network
R-HSA-5684996 MAPK1/MAPK3 signaling
R-HSA-5663202 Diseases of signal transduction
R-HSA-5683057 MAPK family signaling cascades
R-HSA-1643685 Disease

-  Other Names for This Gene
  Alternate Gene Symbols: B5A957, ENST00000261799.1, ENST00000261799.2, ENST00000261799.3, ENST00000261799.4, ENST00000261799.5, ENST00000261799.6, ENST00000261799.7, ENST00000261799.8, NM_002609, P09619, PDGFR, PDGFR1, PGFRB_HUMAN, Q8N5L4, uc317gtu.1, uc317gtu.2
UCSC ID: ENST00000261799.9_7
RefSeq Accession: NM_002609.4
Protein: P09619 (aka PGFRB_HUMAN)

-  GeneReviews for This Gene
  GeneReviews article(s) related to gene PDGFRB:
bgc (Primary Familial Brain Calcification)
dystonia-ov (Hereditary Dystonia Overview)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.